U.S. Patient and Trader Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of informa-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10623957				
Filing Date		2003-07-21				
First Named Inventor	John	nson et al.				
Art Unit		3733				
Examiner Name David		C, Comstock				
Attorney Docket Numb	er	1842-0019				

			Remove			
Examiner Cite Patent Number Kind Code1		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	5836948	B1	1998-11-17	Zucherman et al.	
	2	6190414	B2	2001-02-20	Young et al.	
	3	6436142	B2	2002-08-20	Paes et al.	
	4	6562074	B2	2003-05-13	Gerbec et al.	
	5	4863476	B1	1989-09-05	Shepperd	
	6	5860977	B1	1999-01-19	Zucherman et al.	
	7	6852126	B2	2005-02-08	Ahigren	
If you wis	h to a	dd additional U.S. Pa	tent citatio	n information p	lease click the Add button.	Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10623957
iling Date		2003-07-21
irst Named Inventor	John	son et al.
Art Unit		3733
Examiner Name	David	C. Comstock
		1842 0040

Examiner Initial*	Cite No	Publication Number	Kind Code ¹			Name of Patentee or Applicant R		Relev	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1	20020177897	A1	2002-11-28		Michelson					
	2	20030171812	A1	2003-09-11 Grun		Grunberg et al.					
	3	20050149194	A1	2005-07	-07	Ahigren					
If you wis	h to a	dd additional U.S. Pub	lished Ap	plication	citatio	n information p	olease click the Ade	d butto	n. Add		
				FOREIG	3N PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²				e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		тя	
	1										
If you wisl	h to a	ı dd additional Foreign I	Patent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* No (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city andicir country where published.							T5				
	1										
If you wis	h to a	dd additional non-pate	nt literatu	re docu	ment cit	ation informat	ion please click the	Add b	utton Adi	d	_
,						R SIGNATUR	-				_
Examiner	Signa	ature					Date Conside	ered			_
*EXAMIN	ER: Ir	itial if reference consi	dered, wh	ether or	not cits	ation is in conf	ormance with MPE	P 609	Draw line	through a	_

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10623957	
	Filing Date		2003-07-21	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	John	son et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		3733	
(Not for Submission under or or it many	Examiner Name David		d C. Comstock	
	Attorney Docket Numb	er	1842-0019	

See Kind Code of USPTO Petert Documents at invest, ISETIG.ODV or MEPF 961.04. It better dots that issued the document, by the lockletic code (WIPO Standard S13.) If the planeses patient document, the includation of the parent for the grant or the representation process the sensal number of the patient for sensal for some of the parent for the patient for patient f

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10623957
Filing Date		2003-07-21
First Named Inventor	John	son et al.
Art Unit		3733
Examiner Name	David	C. Comstock
Attorney Docket Numb	er	1842-0019

CERTIFICATION STATEMENT

				selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to 3 any individual designated in 37 CFR 1/50(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Michael D. Beck/	Date (YYYY-MM-DD)	2006-12-04
Name/Print	Michael D. Reck	Registration Number	32 722

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DING SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.